KPV (Lysine-Proline-Valine) is a naturally occurring tripeptide derived from the C-terminal end of alpha-melanocyte stimulating hormone (α-MSH). Despite being only three amino acids long, KPV retains the powerful anti-inflammatory properties of the much larger parent molecule.
What makes KPV particularly interesting in research is its mechanism — rather than acting through cell surface receptors like most peptides, KPV can penetrate cell membranes and directly modulate intracellular inflammatory signaling cascades.
Research Applications
Key research areas include:
- Inflammatory bowel disease: Colitis models showing mucosal healing and reduced inflammation
- Dermatological: Contact dermatitis, allergic skin inflammation models
- Antimicrobial: Direct antimicrobial activity against Staphylococcus aureus and Candida albicans
- General anti-inflammatory: NF-κB inhibition across multiple tissue types
Dosage Information (Research Use)
Research protocols vary by administration route:
- Subcutaneous: 200-500 mcg/day in research models
- Oral: Higher doses studied due to first-pass considerations, though notable oral bioavailability for a peptide
- Topical: Studied in dermatological models at various concentrations
Research use only. No standardized human protocols exist.
Reconstitution & Handling
Standard reconstitution with bacteriostatic water. Due to its small size, KPV dissolves rapidly.
Half-Life & Pharmacokinetics
Short plasma half-life typical of tripeptides, but intracellular accumulation extends functional duration.
Reported Observations in Literature
Limited adverse effects reported in published research. The compound lacks melanocortin receptor activity, avoiding the tanning and appetite effects associated with other MSH-derived peptides.
Key Research References
- Dalmasso G, et al. “The anti-inflammatory peptide KPV attenuates DSS colitis.” PLoS One. 2008
- Brzoska T, et al. “α-Melanocyte-stimulating hormone and related tripeptides.” Endocr Rev. 2008